Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

diseases.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.

In addition to LX2931, Lexicon has three other drug candidates progressing through Phase 2 clinical trials:  LX4211, an orally-delivered, once-daily, dual inhibitor of sodium glucose transporter 1 (SGLT1) and SGLT2 for type 2 diabetes; LX1031, a locally-acting serotonin synthesis inhibitor for irritable bowel syndrome; and LX1032, a peripherally-available serotonin synthesis inhibitor for carcinoid syndrome.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to the characterization of the safety profile of LX2931 observed in the Phase 2 clinical trial as favorable, the characterization of the results of the Phase 2 clinical trial of LX2931 as demonstrating a preliminary signal of efficacy and supporting further study as a potential treatment for rheumatoid arthritis, the mechanism of action of LX2931, and the potential therapeutic and commercial potential of LX2931 generally. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other m
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... ENDO 2013, the Endocrine Society,s 95 th ... both melatonin and cortisol rhythms. This effect further ... clock and address the circadian desynchrony which is ... and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study ...
(Date:6/17/2013)... 17, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... has filed a preliminary prospectus supplement to its effective shelf ... similar filing with securities regulatory authorities in each of the ... a public offering of its common shares to raise gross ... Company will also grant to the underwriters of the Offering ...
(Date:6/17/2013)... June 17, 2013 The following is a Statement ... at Drugfree.org :   Last Friday, ... was halting the sale of prescription drug paraphernalia products. The ... that from time to time there may be individual items ... As a result of this misinterpretation we are electing to ...
Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4A Win for Families: Urban Outfitters Halts Prescription Drug Paraphernalia Product Sales 2
... it has been selected as a Finalist ... list honoring the year,s most promising private technology ventures ... The Red Herring editorial team selected the most innovative ... America. The nominees are evaluated on both quantitative and ...
... a full-service pharmacy benefit management and ancillary medical ... Craig Rollins has joined the organization as Vice ... role he will be responsible for the strategic ... 1Click Ancillary online marketplace. myMatrixx launched 1Click Ancillary ...
Cached Medicine Technology:DICOM Grid Selected as a Finalist for the 2012 Red Herring Top 100 Americas Award 2myMatrixx Names Craig Rollins, Vice President of Ancillary and Business Development 2
(Date:6/17/2013)... OAK BROOK, Ill. In a study of more ... of the abdominal aorta the amount of plaque ... are associated with future cardiovascular events, such as ... are published online in the journal Radiology . ... that atherosclerosis in an artery outside the heart is ...
(Date:6/17/2013)... distribution of white matter brain abnormalities in some patients ... found in early Alzheimer,s dementia, according to a new ... , "Findings of MTBI bear a striking resemblance ... study,s lead author, Saeed Fakhran, M.D., assistant professor of ... of Pittsburgh School of Medicine. "Additional research may help ...
(Date:6/17/2013)... social media push boosted the number of people who ... day, Johns Hopkins researchers found, suggesting social media might ... shortage in the United States. , The gains were ... created a way for users to share their organ ... make their status official on state department of motor ...
(Date:6/17/2013)... (PRWEB) June 17, 2013 Daily Gossip ... therefore, publish a thorough review of the Tinnitus ... Daily Gossip presents the natural treatment that ... patients who have tested it. , Based on the ... natural Tinnitus treatment suggested by Thomas Coleman ...
(Date:6/17/2013)... (PRWEB) June 17, 2013 Nearly 26 ... as many as 79 million adults are estimated to ... to prevent type 2 diabetes through weight loss and ... can help bring your blood sugar level back within ... and factors, 101 Medical Weight Loss physicians can help ...
Breaking Medicine News(10 mins):Health News:Atherosclerosis in abdominal aorta may signal future heart attack, stroke 2Health News:Concussion patients show Alzheimer's-like brain abnormalities 2Health News:Concussion patients show Alzheimer's-like brain abnormalities 3Health News:The Facebook effect: Social media dramatically boosts organ donor registration 2Health News:The Facebook effect: Social media dramatically boosts organ donor registration 3Health News:Thomas Coleman's Tinnitus Miracle Treatment Review Discloses Alternative Natural Cure 2Health News:Best Diet Plans for Diabetics; Tips from 101 Medical Weight Loss 2Health News:Best Diet Plans for Diabetics; Tips from 101 Medical Weight Loss 3Health News:Best Diet Plans for Diabetics; Tips from 101 Medical Weight Loss 4
... Seagull Technology,Pty Ltd, has developed a non-invasive drug delivery ... Australia,s leading cause of,blindness and severe vision loss -- ... retina which affects one in seven people over,the age ... ultrasound (sound,waves) in a handheld device to send drugs ...
... the largest,provider of business services to orthodontic and ... by adding an experienced,marketing professional to its team. ... will work out of the company,s,Metairie office., ... our team to,provide our doctors creative cutting edge ...
... Runyon Cancer Research Foundation named 14 new Damon ... Committee review. The recipients of this prestigious, ... and translational cancer research in the laboratories of ... Fellowship is specifically intended to encourage the nation,s ...
... a woman,s eggs to deteriorate in quality with age, and ... choose an egg -- out of a stash of roughly ... the ovary be influenced to pick a "good" quality egg ... questions are much on the mind of fertility researcher Teresa ...
... vessels, researchers say , , THURSDAY, June 19 (HealthDay News) ... role in allowing experts to see the many reds, ... a report by researchers at the Massachusetts Institute of ... minor players in brain activity, receive signals directly from ...
... We Make A Life By What We Give is the ... about their lives and how they can share what they have ... and Riley Hospital for Children physician-philosopher Richard B. Gunderman, M.D., Ph.D. ... giving in their lives. , In the book, Dr. Gunderman expands ...
Cached Medicine News:Health News:Revolutionary Therapy: Needle-Free Technology for the Treatment Of Blinding Eye Disease 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators 4Health News:New photo 'op' for ovaries may solve some mysteries of infertility 2Health News:Star-Shaped Brain Cells Make Scans Possible 2
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
... These patented ACS lenses offer the ... view as the original clariVits. The simple ... while maintaining its integrity during surgery. Simply ... contact element, then lock together for use. ...
... magnification, indirect, contact, vitrectomy lens available! ... the surgical management of macular holes, ... submacular surgery. The magnification of the ... of a plano/concave direct imaging vitrectomy ...
... XL is recommended for evaluating ... fundus and in the management ... the ideal lens for small ... operating microscope. It provides a ...
Medicine Products: